The inflammatory kinase IKKα phosphorylates and stabilizes c-Myc and enhances its activity.


Journal

Molecular cancer
ISSN: 1476-4598
Titre abrégé: Mol Cancer
Pays: England
ID NLM: 101147698

Informations de publication

Date de publication:
18 01 2021
Historique:
received: 31 07 2020
accepted: 04 01 2021
entrez: 19 1 2021
pubmed: 20 1 2021
medline: 13 8 2021
Statut: epublish

Résumé

The IκB kinase (IKK) complex, comprising the two enzymes IKKα and IKKβ, is the main activator of the inflammatory transcription factor NF-κB, which is constitutively active in many cancers. While several connections between NF-κB signaling and the oncogene c-Myc have been shown, functional links between the signaling molecules are still poorly studied. Molecular interactions were shown by co-immunoprecipitation and FRET microscopy. Phosphorylation of c-Myc was shown by kinases assays and its activity by improved reporter gene systems. CRISPR/Cas9-mediated gene knockout and chemical inhibition were used to block IKK activity. The turnover of c-Myc variants was determined by degradation in presence of cycloheximide and by optical pulse-chase experiments.. Immunofluorescence of mouse prostate tissue and bioinformatics of human datasets were applied to correlate IKKα- and c-Myc levels. Cell proliferation was assessed by EdU incorporation and apoptosis by flow cytometry. We show that IKKα and IKKβ bind to c-Myc and phosphorylate it at serines 67/71 within a sequence that is highly conserved. Knockout of IKKα decreased c-Myc-activity and increased its T58-phosphorylation, the target site for GSK3β, triggering polyubiquitination and degradation. c-Myc-mutants mimicking IKK-mediated S67/S71-phosphorylation exhibited slower turnover, higher cell proliferation and lower apoptosis, while the opposite was observed for non-phosphorylatable A67/A71-mutants. A significant positive correlation of c-Myc and IKKα levels was noticed in the prostate epithelium of mice and in a variety of human cancers. Our data imply that IKKα phosphorylates c-Myc on serines-67/71, thereby stabilizing it, leading to increased transcriptional activity, higher proliferation and decreased apoptosis.

Sections du résumé

BACKGROUND
The IκB kinase (IKK) complex, comprising the two enzymes IKKα and IKKβ, is the main activator of the inflammatory transcription factor NF-κB, which is constitutively active in many cancers. While several connections between NF-κB signaling and the oncogene c-Myc have been shown, functional links between the signaling molecules are still poorly studied.
METHODS
Molecular interactions were shown by co-immunoprecipitation and FRET microscopy. Phosphorylation of c-Myc was shown by kinases assays and its activity by improved reporter gene systems. CRISPR/Cas9-mediated gene knockout and chemical inhibition were used to block IKK activity. The turnover of c-Myc variants was determined by degradation in presence of cycloheximide and by optical pulse-chase experiments.. Immunofluorescence of mouse prostate tissue and bioinformatics of human datasets were applied to correlate IKKα- and c-Myc levels. Cell proliferation was assessed by EdU incorporation and apoptosis by flow cytometry.
RESULTS
We show that IKKα and IKKβ bind to c-Myc and phosphorylate it at serines 67/71 within a sequence that is highly conserved. Knockout of IKKα decreased c-Myc-activity and increased its T58-phosphorylation, the target site for GSK3β, triggering polyubiquitination and degradation. c-Myc-mutants mimicking IKK-mediated S67/S71-phosphorylation exhibited slower turnover, higher cell proliferation and lower apoptosis, while the opposite was observed for non-phosphorylatable A67/A71-mutants. A significant positive correlation of c-Myc and IKKα levels was noticed in the prostate epithelium of mice and in a variety of human cancers.
CONCLUSIONS
Our data imply that IKKα phosphorylates c-Myc on serines-67/71, thereby stabilizing it, leading to increased transcriptional activity, higher proliferation and decreased apoptosis.

Identifiants

pubmed: 33461590
doi: 10.1186/s12943-021-01308-8
pii: 10.1186/s12943-021-01308-8
pmc: PMC7812655
doi:

Substances chimiques

Proto-Oncogene Proteins c-myc 0
Phosphothreonine 1114-81-4
Phosphoserine 17885-08-4
I-kappa B Kinase EC 2.7.11.10

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16

Références

Signal Transduct Target Ther. 2018 Feb 23;3:5
pubmed: 29527331
Genes (Basel). 2017 Feb 16;8(2):
pubmed: 28212321
Oncogene. 2006 Oct 30;25(51):6680-4
pubmed: 17072321
Oncotarget. 2017 Aug 7;8(32):53886
pubmed: 28881858
Mol Cell Biol. 2002 May;22(10):3549-61
pubmed: 11971985
Semin Cancer Biol. 1997 Apr;8(2):63-73
pubmed: 9299584
Expert Opin Ther Targets. 2007 Feb;11(2):133-44
pubmed: 17227230
Nature. 2003 Jun 5;423(6940):659-63
pubmed: 12789343
Cell. 1993 Jan 29;72(2):233-45
pubmed: 8425220
Mol Cell Biol. 1994 Feb;14(2):1039-44
pubmed: 8289784
BMC Cell Biol. 2010 Feb 22;11:15
pubmed: 20175925
Oncotarget. 2017 Aug 7;8(32):53887
pubmed: 28881859
Mol Cancer. 2013 Aug 02;12:86
pubmed: 23915189
Comput Struct Biotechnol J. 2019 Feb 07;17:251-262
pubmed: 30867890
Cancer Cell. 2020 Feb 10;37(2):200-215.e5
pubmed: 32049046
J Biol Chem. 2003 Jan 17;278(3):1450-6
pubmed: 12403772
Cold Spring Harb Perspect Biol. 2009 Nov;1(5):a000141
pubmed: 20066113
Cell Rep. 2012 Oct 25;2(4):840-54
pubmed: 23041317
Cytokine Growth Factor Rev. 2008 Apr;19(2):157-65
pubmed: 18308615
Cell Signal. 2006 Nov;18(11):1941-6
pubmed: 16616828
Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9085-90
pubmed: 15150404
PLoS One. 2013;8(3):e59292
pubmed: 23527154
Nature. 2004 Apr 8;428(6983):660-4
pubmed: 15071597
Mol Cell. 2019 Aug 22;75(4):669-682.e5
pubmed: 31302002
Oncogene. 2008 Aug 14;27(35):4809-19
pubmed: 18438430
Immunol Rev. 2012 Mar;246(1):239-53
pubmed: 22435559
Mol Cell Biol. 2004 Oct;24(19):8541-55
pubmed: 15367674
Nat Biotechnol. 2006 Apr;24(4):461-5
pubmed: 16550175
Biochim Biophys Acta. 2016 Feb;1863(2):205-218
pubmed: 26554849
Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17202-7
pubmed: 17079494
Nature. 2007 Apr 5;446(7136):690-4
pubmed: 17377533
Cancer Res. 2007 Oct 1;67(19):9158-68
pubmed: 17909021
Mol Cell. 2007 Apr 13;26(1):75-87
pubmed: 17434128
Front Immunol. 2019 Feb 04;10:85
pubmed: 30778349
Mol Cell. 2004 Oct 22;16(2):245-55
pubmed: 15494311
J Biol Chem. 2001 Nov 9;276(45):42276-86
pubmed: 11527961
J Biol Chem. 2002 Mar 29;277(13):10842-51
pubmed: 11801607
Nat Cell Biol. 2004 Apr;6(4):308-18
pubmed: 15048125
J Mol Cell Biol. 2012 Jun;4(3):153-63
pubmed: 22561840
Sci Rep. 2019 Jun 3;9(1):8233
pubmed: 31160659
Nature. 2003 Jun 5;423(6940):655-9
pubmed: 12789342
Mod Pathol. 2008 Sep;21(9):1156-67
pubmed: 18567993
Future Oncol. 2005 Feb;1(1):67-78
pubmed: 16555977
Genes Dev. 2004 Sep 15;18(18):2195-224
pubmed: 15371334
Cancer Cell. 2003 Sep;4(3):223-38
pubmed: 14522256
Pharm Res. 2011 Jun;28(6):1357-69
pubmed: 21191633
Adv Bioinformatics. 2008;2008:420747
pubmed: 19956698
Biotechnol J. 2017 Jan;12(1):
pubmed: 27420480
Nat Protoc. 2013 Nov;8(11):2281-2308
pubmed: 24157548
Cancer Cell. 2013 May 13;23(5):647-59
pubmed: 23602409
Mol Cancer. 2011 May 16;10:53
pubmed: 21575199

Auteurs

Bernhard Moser (B)

Institute of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstraße 17, 1090, Vienna, Austria.

Bernhard Hochreiter (B)

Institute of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstraße 17, 1090, Vienna, Austria.

José Basílio (J)

Institute of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstraße 17, 1090, Vienna, Austria.

Viola Gleitsmann (V)

Institute of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstraße 17, 1090, Vienna, Austria.

Anja Panhuber (A)

Institute of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstraße 17, 1090, Vienna, Austria.

Alan Pardo-Garcia (A)

Institute of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstraße 17, 1090, Vienna, Austria.

Bastian Hoesel (B)

Institute of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstraße 17, 1090, Vienna, Austria.

Manuel Salzmann (M)

Institute of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstraße 17, 1090, Vienna, Austria.

Ulrike Resch (U)

Institute of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstraße 17, 1090, Vienna, Austria.

Mamoona Noreen (M)

Institute of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstraße 17, 1090, Vienna, Austria.

Johannes A Schmid (JA)

Institute of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Schwarzspanierstraße 17, 1090, Vienna, Austria. johannes.schmid@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH